Current guidelines for the management of small cell lung cancer

Mayo Clinic Proceedings

Volumn 74, Issue 8, 1999, Pages 809-816

  Adjei, Alex A ^a   Marks, Randolph S ^b   Bonner, James A ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ALGORITHM; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; PRACTICE GUIDELINE; REVIEW; THORACOTOMY; TREATMENT PLANNING;

EID: 0032805404     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.8.809     Document Type: Review

References (70)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. ÇA Cancer J Clin. 1998;48:6-29.
2. Cook RM, Miller YE, Bunn PA Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Prob! Cancer. 1993;17:69-141.
3. Sorensen M, Lassen U, Hansen HH. Current therapy of small cell lung cancer. Curr Opin Oncol. 1998;10:133-138.
4. Souhami RL, Law K. Longevity in small lung cancer: a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990;61:584589.
5. Klastersky J, Leleux A. Secondary neoplasms following cancer treatment with a special emphasis on lung tumors. Neoplasma. 1991:38:253-256.
6. Ruckdeschel JC. Therapeutic options for the treatment of small cell and non-small cell lung cancer. Curr Opin Oncol. 1993;5:323334.
7. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer: expanded Southwest Oncology Group experience. Chest. 1991:99:1425-1432.
8. 0sterlind K, S0renson JB. Prognostic factors. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC, eds. Comprehensive Textbook of Thoracic Oncology. Baltimore, Md: Williams & Wilkins; 1996:319-335.
9. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990;61:597-604.
10. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group Data Base. J Clin Oncol. 1990:8:1563-1574.
11. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promoters of lung cancer. Chest. 1993;103(suppl 1):4S11S.
12. Otterson G, Lin A, Kay F. Genetic etiology of lung cancer. Oncology (Hunting!). 1992:6:97-104.
13. Graziano SL, Pfeifer AM, Testa JR, et al. Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes Cancer. 1991:3:283-293.
14. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3pl4.2 is abnormal in lung cancer. Cell. 1996:85:17-26.
15. LaForgia S, Morse B, Levy J, et al. Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sei USA. 1991;88: 5036-5040.
16. Croce CM. Genetic approaches to the study of the molecular basis of human cancer. Cancer Res. 1991;51(suppl 18):5015S5018S.
17. Mackay B, Lukeman JM, Ordonez NO. Tumors of the Lung. Philadelphia, Pa: WB Saunders Co; 1991.
18. Patel AM, Davila DG, Peters SG. Paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc. 1993:68:278-287.
19. Marchioli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin N Am. 1997:7:65-80.
20. Patel AM, Jett JR. Clinical presentation and staging of lung cancer. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC, eds. Comprehensive Textbook of Thoracic Oncology. Baltimore, Md: Williams & Wilkins; 1996:293-318.
21. Hamrick RM III, Murgo AJ. Lactate dehydrogenase values and bone scans as predictors of bone marrow involvement in small-cell lung cancer. Arch Intern Med. 1987;147:1070-1071.
22. Kristjansen PE, Osterlind K, Hansen M. Detection of bone marrow relapse in patients with small cell carcinoma of the lung. Cancer. 1986:58:2538-2541.
23. Campbell LJ, Van der Weyden MB. Hematological, biochemical and bone scan findings in patients with marrow carcinoma. Pathology. 1991:23:198-201.
24. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiât Oncol Biol Phys. 1986:12:771777.
25. Tritz DB, Doll DC, Ringenberg QS, et al. Bone marrow involvement in small cell lung cancer: clinical significance and correlation with routine laboratory variables. Cancer. 1989;63:763766.
26. Shepherd FA. Role of surgery in the management of small cell lung cancer. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC, eds. Comprehensive Textbook of Thoracic Oncology. Baltimore, Md: Williams & Wilkins; 1996:439-455.
27. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994; 106(suppl6):320S-323S.
28. Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical treatment for limited small-cell lung cancer: the University of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Sura. 1991:101:385-393.
29. Salazar OM, Creech RH. The state of the art toward defining the role of radiation therapy in the management of small cell bronchogenic carcinoma. In! J Radiât Oncol Biol Phys. 1980;6:11031117.
30. Turrisi AT III. Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer. Chest. 1993;103(suppl4):418S-422S.
31. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327:1618-1624.
32. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327: 1434-1441.
33. Sandler AB, Buzaid AC. Lung cancer: a review of current therapeutic modalities. Lung. 1992; 170:249-265.
34. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1993;! 1:336-344.
35. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the \\mc.NEnglJMecl. 1987;316:912-918.
36. Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol. 1994; 12:496502.
37. Johnson DH, Kim K, Turrisi AT, et al. Cisplatin (P) and etoposide (E) + concurrent thoracic radiotherapy (TRT) administered once versus twice daily for limited-stage (LS) small cell lung cancer (SCLC): preliminary results of an intergroup trial [abstract]. Program ProcAm Soc Clin Oncol. 1994;13:333.
38. Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Sloan JA. Phase III comparison of once-daily thoracic radiation versus twice-daily thoracic radiation in patients with limited stage small cell lung cancer [abstract]. Program Proc Am Assoc Clin Oncol. 1998; 17: 456a.
39. Bunn PA Jr, Kelly K. Prophylactic cranial irradiation for patients with small-cell lung cancer [editorial]. JNatl Cancer Inst. 1995;87: 161-162.
40. Kristjansen PE, Hansen HH. Prophylactic cranial irradiation in small cell lung cancer-an update. Lung Cancer. 1995;12(suppl 3):S23-S40.
41. Harris DT. Prophylactic cranial irradiation in small-cell lung cancer. Semin Oncol. 1993;20:338-350.
42. Arriagada R, LeChevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87:183-190.
43. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994; 12:627642.
44. Salgia R, Skarin AT, Elias A. Management of limited-stage small cell lung cancer. Adv Oncol. 1996;12:8-15.
45. Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiât Oncol Biol Phys. 1995:33:179-182.
46. Liengswangwong V, Bonner JA, Shaw EG, et al. Prophylactic cranial irradiation in limited-stage small cell lung cancer. Cancer. 1995:75:1302-1309.
47. Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limitedstage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996;14:806813.
48. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985:3:1471-1477.
49. Lowenbraun S, Birch R, Buchanan R, et al. Combination chemotherapy in small cell lung carcinoma: a randomized study of two intensive regimens. Cancer. 1984;54:2344-2350.
50. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Eng! J Med. 1991:325:164-170.
51. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 1987;107:451458.
52. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83:855-861.
53. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10:282-291.
54. Loehrer PJ Sr, Einhorn LH, Greco FA. Cisplatin plus etoposide in small cell lung cancer. Semin Oncol. 1988; 15:2-8.
55. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol. 1987;5:15741578.
56. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989;59:578-583.
57. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung../ Clin Oncol. 1991:9:499-508.
58. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993:329:1848-1852.
59. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994; 12:2022-2034.
60. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol. 1987:5:1864-1873
61. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol. 1990;17(suppl 2):49-53.
62. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet. 1996:348:563-566.
63. Souhami RL, Spiro SO, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. ./ Nail Cancer Inst. 1997:89:577-580.
64. Domine M, Lobo F, Jerves M, Lopez-Sacconi F, Gonzalez Ageitos A, Vicente J. Long term survival with salvage chemotherapy in patients with small cell lung cancer (SCLC) [abstract]. Program Proc Am Soc din Oncol. 1990;9:A-938.
65. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998:77:347-351.
66. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J ClinOncol. 1997; 15:2090-2096.
67. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. / Clin Oncol. 1996:14:27852790.
68. Perez EA, Loprinzi CL, Sloan JA, Owens DT, Novotny PJ, Bonner JA. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer. 1997:80:676-680.
69. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993:119:383-390.
70. Sagman U, Lishner M, Maki E, et al. Second primary malignancies following diagnosis of small-cell lung cancer. J din Oncol. 1992:10:1525-1533.